Transgenomic, Inc. and ApoCell, Inc. Present Results of Lung Cancer Research Study at the 2013 American Society of Clinical Oncology Annual Meeting

Published: Jun 03, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Transgenomic, Inc. (OTCBB: TBIO) and ApoCell, Inc. today announced the results of a research collaboration with the University of Texas MD Anderson Cancer Center that coupled ApoCell’s ApoStream™ platform for isolating circulating tumor cells (CTCs) with Transgenomic’s ICE COLD-PCR technology to detect signature mutations in CTCs isolated from the blood of lung cancer patients.

Help employers find you! Check out all the jobs and post your resume.

Back to news